BR112014009178A2 - métodos, uso, receptor e invenção - Google Patents

métodos, uso, receptor e invenção

Info

Publication number
BR112014009178A2
BR112014009178A2 BR112014009178A BR112014009178A BR112014009178A2 BR 112014009178 A2 BR112014009178 A2 BR 112014009178A2 BR 112014009178 A BR112014009178 A BR 112014009178A BR 112014009178 A BR112014009178 A BR 112014009178A BR 112014009178 A2 BR112014009178 A2 BR 112014009178A2
Authority
BR
Brazil
Prior art keywords
receptor
methods
Prior art date
Application number
BR112014009178A
Other languages
English (en)
Inventor
Freimoser-Grundschober Anne
Jaeger Christiane
Umana Pablo
Sondermann Peter
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of BR112014009178A2 publication Critical patent/BR112014009178A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
BR112014009178A 2011-10-19 2012-10-16 métodos, uso, receptor e invenção BR112014009178A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11185798 2011-10-19
PCT/EP2012/070439 WO2013057078A1 (en) 2011-10-19 2012-10-16 Separation method for fucosylated antibodies

Publications (1)

Publication Number Publication Date
BR112014009178A2 true BR112014009178A2 (pt) 2018-09-04

Family

ID=47019025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009178A BR112014009178A2 (pt) 2011-10-19 2012-10-16 métodos, uso, receptor e invenção

Country Status (12)

Country Link
US (2) US9994610B2 (pt)
EP (1) EP2768845B1 (pt)
JP (2) JP6356605B2 (pt)
KR (1) KR20140077178A (pt)
CN (2) CN108314729A (pt)
BR (1) BR112014009178A2 (pt)
CA (1) CA2851053A1 (pt)
ES (1) ES2619677T3 (pt)
HK (2) HK1199272A1 (pt)
MX (1) MX355048B (pt)
RU (1) RU2650873C2 (pt)
WO (1) WO2013057078A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346523B (es) 2006-09-13 2017-03-23 Abbvie Inc Mejoras de cultivos celulares.
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CN105111309A (zh) 2008-10-20 2015-12-02 Abbvie公司 使用a蛋白亲和层析分离和纯化抗体
SG195577A1 (en) 2008-10-20 2013-12-30 Abbott Lab Viral inactivation during purification of antibodies
EP2734537B1 (en) 2011-07-20 2022-12-21 Zepteon, Incorporated Polypeptide separation methods
JP6451119B2 (ja) * 2014-07-17 2019-01-16 東ソー株式会社 抗体依存性細胞傷害活性の強さに基づき抗体を分離する方法
EP3371202A1 (en) 2015-11-04 2018-09-12 Biogen MA Inc. Conjugation methods for modifying or immobilizing proteins
EP3638765A1 (en) * 2017-04-06 2020-04-22 Flodesign Sonics, Inc. Acoustic perfusion devices
ES2961186T3 (es) * 2019-07-03 2024-03-08 Merck Patent Gmbh Purificación de glicoformas
WO2021010349A1 (ja) * 2019-07-12 2021-01-21 国立大学法人北海道大学 非アルコール性脂肪肝炎の血中線維化マーカーの開発
GB202204016D0 (en) * 2022-03-22 2022-05-04 Ucl Business Plc Affinity chromatography ligands for antibody glycovariant separation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
EP1006183A1 (en) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
PL222219B1 (pl) 2003-01-22 2016-07-29 Glycart Biotechnology Ag Komórka gospodarza i sposób wytwarzania polipeptydu w komórce gospodarza
CN101098890B (zh) * 2004-11-12 2012-07-18 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US7699979B2 (en) * 2005-01-07 2010-04-20 Board Of Trustees Of The University Of Arkansas Separation system and efficient capture of contaminants using magnetic nanoparticles
JP5150488B2 (ja) * 2005-06-17 2013-02-20 ワイス・エルエルシー Fc領域含有タンパク質を精製する方法
US20120021484A1 (en) * 2008-10-22 2012-01-26 Biogen Idec Ma Inc. Recombinant FcRn and Variants Thereof for Purification of Fc-Containing Fusion Proteins
US20120196310A1 (en) 2009-10-02 2012-08-02 Christiane Jaeger A-fucosylation detection in antibodies
EP2734537B1 (en) * 2011-07-20 2022-12-21 Zepteon, Incorporated Polypeptide separation methods

Also Published As

Publication number Publication date
HK1199272A1 (en) 2015-06-26
US20140255399A1 (en) 2014-09-11
ES2619677T3 (es) 2017-06-26
CN103890002A (zh) 2014-06-25
EP2768845A1 (en) 2014-08-27
CA2851053A1 (en) 2013-04-25
JP2018184406A (ja) 2018-11-22
MX355048B (es) 2018-04-03
US9994610B2 (en) 2018-06-12
JP6356605B2 (ja) 2018-07-11
JP2014530829A (ja) 2014-11-20
RU2014118552A (ru) 2015-11-27
EP2768845B1 (en) 2017-01-18
KR20140077178A (ko) 2014-06-23
WO2013057078A1 (en) 2013-04-25
MX2014004604A (es) 2014-05-27
RU2650873C2 (ru) 2018-04-17
HK1258766A1 (zh) 2019-11-22
US20180265544A1 (en) 2018-09-20
CN108314729A (zh) 2018-07-24

Similar Documents

Publication Publication Date Title
BR112014009178A2 (pt) métodos, uso, receptor e invenção
BR112012031232A2 (pt) método, dispositivo e uso
BR112013033308A2 (pt) assento
DK2539214T3 (da) Forbedret sædestøtte
FI20105532A0 (fi) Istuinjärjestely
DK2568854T3 (da) Sædeindretning
BR112014009476A2 (pt) refletor, iluminador e uso do iluminador
BR112014014504A2 (pt) uso de partícula
BR112015004876A2 (pt) construção de cadeiras
BR112013012175A2 (pt) combinação, coadministração, uso e método
BR112013003504A2 (pt) encosto traseiro unitário
BR112014010432A2 (pt) uso médico
BR112014006117A2 (pt) dispositivo de assento à prova de minas
BR112014006742A2 (pt) unidade de dobramento-estiramento, e, dispositivo de fiação-tricotagem
DK2592971T3 (da) Siddeanordning
BR112013016120A2 (pt) elevador ciclônico e métodos para uso do mesmo.
FI20100353A (fi) Iskulaite
ES1073433Y (es) Asiento para tareas pluriposturales
ES1076210Y (es) Colillero para uso publico.
ITGE20100015U1 (it) Scb - essecibi (sedile/coperchio - bidè)
FI8749U1 (fi) Istuin
UA23896S (uk) Сидіння
UA23895S (uk) Сидіння
UA23893S (uk) Сидіння
UA23576S (uk) Сидіння

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements